SCHEMBL17276017

SCHEMBL17276017

Nc1nc2c(F)c(Cl)ccc2[nH]1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NUDT1 P36639 5/20 0.49
MMP12 P39900 3/20 0.44
HTR3E A5X5Y0 1/20 0.41
HTR3B O95264 1/20 0.41
HTR3A P46098 1/20 0.41
BACE1 P56817 1/20 0.41
HTR3D Q70Z44 1/20 0.41
HTR3C Q8WXA8 1/20 0.41
CDK5 Q00535 7/20 0.39
CDK5R1 Q15078 7/20 0.39
ULK1 O75385 1/20 0.37
CDK7 P50613 1/20 0.37
PRKCE Q02156 1/20 0.37
CAMK2G Q13555 1/20 0.37
DYRK1A Q13627 1/20 0.37
RPS6KA1 Q15418 1/20 0.37
AAK1 Q2M2I8 1/20 0.37
MAP3K19 Q56UN5 1/20 0.37
CAMKK1 Q8N5S9 1/20 0.37
CAMKK2 Q96RR4 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7045259 0.81 NUDT1 (0.60) NUDT1MMP12HTR3EHTR3BHTR3A
SCHEMBL17276023 0.81 HRH4 (0.42) NUDT1MMP12HTR3EHTR3BHTR3A
SCHEMBL17276058 0.78 MMP12 (0.44) NUDT1MMP12CDK5CDK5R1ULK1
SCHEMBL17276081 0.78 NUDT1 (0.49) NUDT1MMP12HTR3EHTR3BHTR3A
SCHEMBL17276018 0.78 NUDT1 (0.49) NUDT1MMP12HTR3EHTR3BHTR3A
Hydrochloric Acid SCHEMBL23497511 0.76 CACNA1H (0.36) ALDH1A1NPC1GAARAB9A
SCHEMBL17276038 0.74 NUDT1 (0.37) NUDT1CDK5CDK5R1ULK1CDK7
SCHEMBL17276044 0.74 NUDT1 (0.45) NUDT1MMP12HTR3EHTR3BHTR3A
SCHEMBL215756 0.73 NUDT1 (0.70) NUDT1MMP12HTR3EHTR3BHTR3A
SCHEMBL17276062 0.69 NUDT1 (0.51) NUDT1CDK5CDK5R1ULK1CDK7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9771372-B2 Compounds useful as S100-inhibitors ACTIVE BIOTECH AB (SE) 2017-09-26 US disclosed
US-20170204098-A1 NOVEL COMPOUNDS USEFUL AS S100-INHIBITORS ACTIVE BIOTECH AB (SE) 2017-07-20 US disclosed
EP-2991990-B1 NOVEL COMPOUNDS USEFUL AS S100-INHIBITORS ACTIVE BIOTECH AB (SE) 2017-02-01 EP disclosed
EP-2991990-A1 NOVEL COMPOUNDS USEFUL AS S100-INHIBITORS Active Biotech AB (SE) 2016-03-09 EP disclosed
WO-2015177367-A1 NOVEL COMPOUNDS USEFUL AS S100-INHIBITORS ACTIVE BIOTECH AB (SE) 2015-11-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170204098-A1 NOVEL COMPOUNDS USEFUL AS S100-INHIBITORS S100A9, S100A4, S100B NUDT1 2826/4885MMP12 970/4885HTR3E 3359/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.